Tag: PRESS RELEASE

Patients with head-and neck cancer are often treated with radiation therapy. A side-effect to this life saving therapy is reduced salivary production which has serious consequences for mouth- and dental health and quality of life.

Injection of ASCs directly into the salivary glands in a phase I clinical trial has proven safety and promising efficacy. The first of 120 planned patients has been enrolled and treated with ASCs in a double-blind placebo-controlled phase II trial in patients suffering from damaged salivary glands due to radiation-induced hyposalivation and xerostomia.

Heart failure is a serious condition with a high morbidity and mortality. The patient enrolment and 1 year follow-up has been finalized for all heart failure patients in the Danish Ischemic Heart Failure phase II Trial (81 patients), in the International multi-centre SCIENCE Ischemic Heart Failure Phase II Trial (133 patients) and in the Non-Ischemic Heart Failure Phase I-II Trial (30 patients).

All safety and efficacy data will be ready for publication late 2021.

Lung transplantation is the ultimate treatment of patients with severe lung disease. However, the short- and long-term prognosis is still problematic due to immunological reactions towards the transplanted lung.

The first patient has successfully been enrolled in the Chronic Lung Allograft dysfunction (Lung transplant rejection) phase I-II trial. The patients are randomized to a blinded treatment with intravenous infusion of either 100 million ASCs, 200 million ASCs or saline. A total of seven of the planned 30 patients have been enrolled without safety implications.

The nerve conduction system within the heart can be destroyed by a process involving increased fibrosis and inflammation. These patients are currently being treated with pacemakers.

A total of five of the planned 10 patients with left bundle branch block have been treated with direct injection of 18 million ASCs to test whether the treatments can reestablish nerve conduction within the heart.

Sjögren’s syndrome is a serious autoimmune disease that can cause serious eye and vision problems due to reduced tear production.

A phase I trial with direct injection of ASCs into the lacrimal gland has proven safety and efficacy. Based on these data the first of 40 planned patients has been enrolled and treated with ASCs in the double-blind placebo-controlled phase II trial in patients with tear gland malfunction (Aqueous Deficient Dry Eye Disease, Sjögren’s syndrome).